Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Multiple Myeloma 56Recurrence 16Neoplasms, Plasma Cell 11Lymphoma, Mantle-Cell 10Lymphoma, Non-Hodgkin 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma 8Leukemia, Myeloid, Acute 8Lymphoma, Follicular 7Lymphoma, Large B-Cell, Diffuse 5Hematologic Neoplasms 5Waldenstrom Macroglobulinemia 4Neoplasms 4Leukemia 4Carcinoma, Non-Small-Cell Lung 4Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, B-Cell, Marginal Zone 3Lung Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Sezary Syndrome 2Paraproteinemias 2Pancreatic Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell 2Leukemia, Myelomonocytic, Chronic 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2

Interventions

Temozolomide 26Bevacizumab 14Radiosurgery 12Radiotherapy 9pembrolizumab 8Carboplatin 8Trastuzumab 6temsirolimus 5Sirolimus 5Erlotinib Hydrochloride 5abemaciclib 4Paclitaxel 4Irinotecan 4Capecitabine 4tipifarnib 3Sorafenib 3Radiation 3Mental Status and Dementia Tests 3Ipilimumab 3Everolimus 3Aminolevulinic Acid 3130-nm albumin-bound paclitaxel 3tucatinib 2pertuzumab 2fludarabine 2durvalumab 2alovudine 2alectinib 2Vorinostat 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Brain Neoplasms × Bortezomib × Clear all
NCT00512798 2012-10-02

Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma

Vanderbilt-Ingram Cancer Center

Phase 1/2 Terminated
47 enrolled 9 charts
CNSDermatologic

Brain Neoplasms, Melanoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡